electroCore Q1 Revenue $9.58M, Exceeds Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 06 2026
0mins
Reports Q1 revenue $9.58M, consensus $9.01M. "Our first quarter results reflect what we believe is a meaningful inflection point for electroCore," said Joshua Lev, Interim President and Chief Financial Officer of electroCore. "Quarterly revenue of $9.6 million was our highest ever and was accomplished with 87% gross profit margin. Net loss for the quarter was $5.3 million, however, after removing items such as non-recurring expenses associated with the leadership changes, we exhibited a 24% year-over-year improvement in adjusted EBITDA loss, demonstrating the operating leverage we expect to see as our platform scales. Each of our prescription channels - gammaCore in the VA and our Quell Fibromyalgia franchise acquired from NeuroMetrix, Inc. ("NURO") last year - is contributing meaningfully, while our Truvaga consumer wellness brand continues to grow. With the leadership transition substantially behind us and Michael Fox on board to accelerate revenue growth, we believe we are well-positioned to execute against our full-year guidance."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ECOR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ECOR
Wall Street analysts forecast ECOR stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 8.675
Low
12.00
Averages
15.00
High
18.00
Current: 8.675
Low
12.00
Averages
15.00
High
18.00
About ECOR
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company focused on improving health through its non-invasive vagus nerve stimulation (nVNS) technology platform and related product offerings. The Company’s portfolio also includes Quell, a wearable, app and cloud-enabled neuromodulation platform that is indicated for the treatment of fibromyalgia symptoms and lower-extremity chronic pain. Its product categories include handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headaches, and handheld, personal use consumer products. Its products include gammaCore, Quell Fibromyalgia, Truvaga and TAC-STIM. Its gammaCore Sapphire is a prescription medical device that is used for a variety of primary headache conditions. Truvaga is a personal-use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Multiple Companies See Significant Stock Price Gains
- CODX Stock Surge: Co-Diagnostics Inc. (CODX) saw its stock price jump nearly 80% to $9.11 on Tuesday as it advances the development of its Ebola PCR assay, which is expected to significantly enhance the company's competitiveness in the molecular diagnostics market.
- NRXP Regulatory Catalysts: NRx Pharmaceuticals Inc. (NRXP) shares rose over 30% to $4.31, driven by the anticipation of a New Drug Application submission to the FDA, which is expected to boost the company's market share in the treatment of suicidal depression.
- ECOR Revenue Growth: electroCore Inc. (ECOR) reported a 43% revenue increase in Q1, with expectations of a 30% rise in annual revenue compared to 2025, leading to a 33.58% stock price increase, indicating strong performance in the bioelectronic medicine sector.
- OTLK Regulatory Progress: Outlook Therapeutics Inc. (OTLK) shares jumped over 29% to $0.40 following positive regulatory developments regarding LYTENAVA, with plans to resubmit the Biologics License Application in June 2026, reflecting a strategic shift in their approach to FDA engagement.
See More
electroCore to Participate in LD Micro Invitational XVI Conference
- Conference Participation: electroCore will participate in the LD Micro Invitational XVI Conference on May 18, 2026, at the Luxe Sunset Boulevard Hotel in Los Angeles, showcasing its advancements in bioelectronic medicine, which is expected to attract investor interest.
- Executive Presentation: Interim President and CFO Joshua Lev will deliver a presentation and host one-on-one meetings during the conference, aiming to enhance investor understanding of the company's strategy and products through direct engagement.
- Product Showcase: electroCore's gammaCore® and Quell® products utilize non-invasive neuromodulation technology to treat chronic pain, highlighting the company's innovative capabilities in bioelectronic technology, which may draw more attention from the healthcare sector.
- Health Mission: The company is committed to improving health and quality of life through innovative non-invasive bioelectronic technologies, positioning itself for greater market share in the health tech sector and driving future business growth.
See More
electroCore to Participate in LD Micro Invitational XVI Conference
- Conference Participation: electroCore will participate in the LD Micro Invitational XVI Conference on May 18, 2026, at the Luxe Sunset Boulevard Hotel in Los Angeles, showcasing its innovations in bioelectronic medicine.
- Executive Presentation: Interim President and CFO Joshua Lev will deliver a presentation and host one-on-one meetings, aiming to engage deeply with investors regarding the company's strategic developments.
- Product Showcase: The company highlights its leading products, gammaCore® and Quell®, which utilize non-invasive neuromodulation technology to treat chronic pain, demonstrating its leadership in the bioelectronic technology sector.
- Health Mission: electroCore is committed to improving health and quality of life through innovative non-invasive bioelectronic technologies, further solidifying its market position in the health tech industry.
See More
On-Demand Access to Precious Metals & Critical Minerals Virtual Investor Conference Presentations
- Conference Content Replay: Presentations from the Precious Metals & Critical Minerals Virtual Investor Conference are now available for on-demand viewing, allowing investors, advisors, and analysts to access content 24/7 for 90 days, thereby enhancing convenience and flexibility in information retrieval.
- One-on-One Meeting Arrangements: Selected companies are accepting requests for one-on-one management meetings, enabling investors to communicate directly with company leadership, which enhances interaction and transparency between investors and companies.
- Resource Download Convenience: Attendees can download investor materials from the company's resource section, which not only provides comprehensive information support for investors but also promotes a deeper understanding of the company's business.
- Advantages of Virtual Conferences: Virtual Investor Conferences offer real-time investor engagement solutions that improve the efficiency of connections between companies and investors, marking a new trend in investor relations management, especially among retail and institutional investors globally.
See More
electroCore Q1 2026 Earnings Call Highlights
- Significant Revenue Growth: electroCore reported $9.6 million in revenue for Q1 2026, reflecting a 43% year-over-year increase, indicating accelerated penetration in the VA and Truvaga markets, which enhances its competitive position.
- Margin Improvement: The company expanded its gross margin to 87%, while adjusted EBITDA loss improved by 24% to $2.3 million, demonstrating improvements in cost control and operational efficiency, which bolster future profitability potential.
- Strategic Focus Deepening: New COO Michael Fox emphasized a shift from breadth to depth in the VA market, aiming to increase the number of prescribers per site, thereby enhancing patient coverage and driving revenue growth further.
- Optimistic Future Outlook: The company reaffirmed its full-year 2026 revenue growth guidance of approximately 30% and plans to relaunch the OTC Quell relief product in the second half of the year, showcasing a proactive approach to market opportunities.
See More
ElectroCore to Announce Q1 Earnings on May 6th
- Earnings Announcement: ElectroCore (ECOR) is set to release its Q1 2023 earnings on May 6th after market close, with a consensus EPS estimate of -$0.61, reflecting a 29.8% year-over-year decline, indicating significant profitability challenges.
- Revenue Expectations: Analysts forecast revenue of $9.01 million, representing a 34.5% year-over-year increase; however, the company has not beaten EPS or revenue estimates in the past year, highlighting performance uncertainty.
- Historical Performance: ElectroCore has a track record of 0% in exceeding EPS and revenue estimates over the last year, which may negatively impact investor confidence ahead of the upcoming earnings report.
- Future Potential: Despite the current unfavorable earnings outlook, ElectroCore outlines a potential for 30% revenue growth in 2026, suggesting a possible strategic turnaround following leadership transitions.
See More
Multiple Companies See Significant Stock Price Gains
- CODX Stock Surge: Co-Diagnostics Inc. (CODX) saw its stock price jump nearly 80% to $9.11 on Tuesday as it advances the development of its Ebola PCR assay, which is expected to significantly enhance the company's competitiveness in the molecular diagnostics market.
- NRXP Regulatory Catalysts: NRx Pharmaceuticals Inc. (NRXP) shares rose over 30% to $4.31, driven by the anticipation of a New Drug Application submission to the FDA, which is expected to boost the company's market share in the treatment of suicidal depression.
- ECOR Revenue Growth: electroCore Inc. (ECOR) reported a 43% revenue increase in Q1, with expectations of a 30% rise in annual revenue compared to 2025, leading to a 33.58% stock price increase, indicating strong performance in the bioelectronic medicine sector.
- OTLK Regulatory Progress: Outlook Therapeutics Inc. (OTLK) shares jumped over 29% to $0.40 following positive regulatory developments regarding LYTENAVA, with plans to resubmit the Biologics License Application in June 2026, reflecting a strategic shift in their approach to FDA engagement.
See More
electroCore to Participate in LD Micro Invitational XVI Conference
- Conference Participation: electroCore will participate in the LD Micro Invitational XVI Conference on May 18, 2026, at the Luxe Sunset Boulevard Hotel in Los Angeles, showcasing its advancements in bioelectronic medicine, which is expected to attract investor interest.
- Executive Presentation: Interim President and CFO Joshua Lev will deliver a presentation and host one-on-one meetings during the conference, aiming to enhance investor understanding of the company's strategy and products through direct engagement.
- Product Showcase: electroCore's gammaCore® and Quell® products utilize non-invasive neuromodulation technology to treat chronic pain, highlighting the company's innovative capabilities in bioelectronic technology, which may draw more attention from the healthcare sector.
- Health Mission: The company is committed to improving health and quality of life through innovative non-invasive bioelectronic technologies, positioning itself for greater market share in the health tech sector and driving future business growth.
See More
electroCore to Participate in LD Micro Invitational XVI Conference
- Conference Participation: electroCore will participate in the LD Micro Invitational XVI Conference on May 18, 2026, at the Luxe Sunset Boulevard Hotel in Los Angeles, showcasing its innovations in bioelectronic medicine.
- Executive Presentation: Interim President and CFO Joshua Lev will deliver a presentation and host one-on-one meetings, aiming to engage deeply with investors regarding the company's strategic developments.
- Product Showcase: The company highlights its leading products, gammaCore® and Quell®, which utilize non-invasive neuromodulation technology to treat chronic pain, demonstrating its leadership in the bioelectronic technology sector.
- Health Mission: electroCore is committed to improving health and quality of life through innovative non-invasive bioelectronic technologies, further solidifying its market position in the health tech industry.
See More
On-Demand Access to Precious Metals & Critical Minerals Virtual Investor Conference Presentations
- Conference Content Replay: Presentations from the Precious Metals & Critical Minerals Virtual Investor Conference are now available for on-demand viewing, allowing investors, advisors, and analysts to access content 24/7 for 90 days, thereby enhancing convenience and flexibility in information retrieval.
- One-on-One Meeting Arrangements: Selected companies are accepting requests for one-on-one management meetings, enabling investors to communicate directly with company leadership, which enhances interaction and transparency between investors and companies.
- Resource Download Convenience: Attendees can download investor materials from the company's resource section, which not only provides comprehensive information support for investors but also promotes a deeper understanding of the company's business.
- Advantages of Virtual Conferences: Virtual Investor Conferences offer real-time investor engagement solutions that improve the efficiency of connections between companies and investors, marking a new trend in investor relations management, especially among retail and institutional investors globally.
See More
electroCore Q1 2026 Earnings Call Highlights
- Significant Revenue Growth: electroCore reported $9.6 million in revenue for Q1 2026, reflecting a 43% year-over-year increase, indicating accelerated penetration in the VA and Truvaga markets, which enhances its competitive position.
- Margin Improvement: The company expanded its gross margin to 87%, while adjusted EBITDA loss improved by 24% to $2.3 million, demonstrating improvements in cost control and operational efficiency, which bolster future profitability potential.
- Strategic Focus Deepening: New COO Michael Fox emphasized a shift from breadth to depth in the VA market, aiming to increase the number of prescribers per site, thereby enhancing patient coverage and driving revenue growth further.
- Optimistic Future Outlook: The company reaffirmed its full-year 2026 revenue growth guidance of approximately 30% and plans to relaunch the OTC Quell relief product in the second half of the year, showcasing a proactive approach to market opportunities.
See More
ElectroCore to Announce Q1 Earnings on May 6th
- Earnings Announcement: ElectroCore (ECOR) is set to release its Q1 2023 earnings on May 6th after market close, with a consensus EPS estimate of -$0.61, reflecting a 29.8% year-over-year decline, indicating significant profitability challenges.
- Revenue Expectations: Analysts forecast revenue of $9.01 million, representing a 34.5% year-over-year increase; however, the company has not beaten EPS or revenue estimates in the past year, highlighting performance uncertainty.
- Historical Performance: ElectroCore has a track record of 0% in exceeding EPS and revenue estimates over the last year, which may negatively impact investor confidence ahead of the upcoming earnings report.
- Future Potential: Despite the current unfavorable earnings outlook, ElectroCore outlines a potential for 30% revenue growth in 2026, suggesting a possible strategic turnaround following leadership transitions.
See More
